CIPLACipla
Pharma · Pharmaceuticals · NSE · as of 2026-07-20 (delayed ~30 min in market hours)
₹1,441.60
▲ 1.61%Decent
Price & Volume
Loading chart…
Key Ratios
Market Cap (₹ cr)1,14,609.00
P/E29.54
P/B3.33
PEG—
ROE %11.74
ROCE %13.80
Debt / Equity0.02
EPS48.03
Revenue Growth %-2.10
Profit Growth %-54.60
Dividend Yield %0.92
Promoter Holding %31.12
FII Holding %44.04
DII Holding %—
Beta0.11
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
| Golden Cross | LONG | 72% | ₹1,441.60 | ₹1,398.95 | ₹1,526.90 | 2.00 |
| Pullback to 21-EMA | LONG | 71% | ₹1,441.60 | ₹1,404.00 | ₹1,527.70 | 2.29 |
HOLDConviction 66%
The picture
- • Debt/Equity: 0.02
- • Valuation vs sector: P/E 29.5 vs sector 38.6
- • RSI: 56
- • Price vs EMA21: above
- • Price vs SMA50: above
- • 1-month vs NIFTY: +6.4% relative
- • Golden Cross signal (setup quality 72%)
- • Pullback to 21-EMA signal (setup quality 71%)
Bull case
- • Debt/Equity: 0.02
- • Valuation vs sector: P/E 29.5 vs sector 38.6
- • RSI: 56
- • Price vs EMA21: above
Bear case
- • Revenue growth: -2.1% YoY
- • Profit growth: -54.6% YoY
- • MACD: bearish
- • Volume trend: 0.6x baseline
Key risks
- • Weak fundamentals — technical strength may not sustain
- • Revenue growth: -2.1% YoY
- • Profit growth: -54.6% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Entry (CMP)
₹1,441.60
Stop Loss
₹1,389.96
risk 3.6%
Target 1 (1.5R)
₹1,519.06
+5.4%
Target 2 (3R)
₹1,596.52
+10.7%
Support (20d)
₹1,404.00
Resistance (52w)
₹1,657.45
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹51.64/share
ATR (volatility)
₹27.93
avg daily range
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹27.93). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.
Score Breakdown
Fundamental
41
Technical
67
Momentum
68
Risk (safety)
70